Am J Surg

1. ROZANI S, Lykoudis PM
   The impact of intestinal and mammary microbiomes on breast cancer development: A review on the microbiota and oestrobolome roles in tumour microenvironments.
   Am J Surg. 2024 Jun 5:115795. doi: 10.1016/j.amjsurg.2024.115795.
   

   >> Share

   
   
2. JIN Z, Al Qaysi N, Hanna M, Moses V, et al
   Surgical excision versus clinical follow-up: Outcomes of benign intraductal papillomas diagnosed on core needle biopsy.
   Am J Surg. 2024;233:114-119.
   

   >> Share

   
   
3. BOTTY VAN DEN BRUELE A, Paul MA, Thomas SM, Sammons SL, et al
   Axillary nodal disease burden is not associated with an elevated 21-gene recurrence score in post-menopausal women presenting with a clinically negative axilla.
   Am J Surg. 2024;233:45-51.
   

   >> Share

   
   

   
   Ann Surg Oncol

4. CHU JJ, Tadros AB, Vingan PS, Assel MJ, et al
   ASO Visual Abstract: Remote Symptom Monitoring with Clinical Alerts Following Mastectomy: Do Early Symptoms Predict 30-Day Surgical Complications.
   Ann Surg Oncol. 2024;31:4547-4548.
   

   >> Share

   
   
5. CARROLL JF, Hoskin TL, Leon-Ferre RA, Boughey JC, et al
   Impact of Presenting Stage on Overall Survival in Patients Treated with Neoadjuvant Chemotherapy for Triple Negative Breast Cancer.
   Ann Surg Oncol. 2024 Jun 13. doi: 10.1245/s10434-024-15583.
   

   >> Share

   
   
6. LEE EG, Lee DE, Jung SY, Han JH, et al
   ASO Visual Abstract: Clinical Application of Multimodal Sentinel Lymph Node Mapping Method in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy: An Interim Analysis.
   Ann Surg Oncol. 2024 Jun 12. doi: 10.1245/s10434-024-15482.
   

   >> Share

   
   
7. MISHRA A, Deo SVS, Kumar N, Bansal B, et al
   A Prospective Questionnaire-Based Study Evaluating Genetic Literacy and Impact of Brief Educational Intervention Among Breast Cancer Patients in a Low- to Middle-Income Country.
   Ann Surg Oncol. 2024 Jun 11. doi: 10.1245/s10434-024-15527.
   

   >> Share

   
   
8. KING TA, Mittendorf EA
   Breast Articles From 2023: Informing Practice Across the Continuum of Care.
   Ann Surg Oncol. 2024;31:4470-4476.
   

   >> Share

   
   
9. SETO Y, Ishitobi M, Nakayama T
   ASO Author Reflections: Do Patients with Ipsilateral Breast Tumor Recurrence Prefer Repeat Breast-Conserving Surgery or Mastectomy?
   Ann Surg Oncol. 2024;31:4540.
   

   >> Share

   
   
10. SETO Y, Ishitobi M, Shien T, Oshiro C, et al
    Patient Preference for Surgical Methods for Ipsilateral Breast Tumor Recurrence.
    Ann Surg Oncol. 2024;31:4512-4517.
    

    >> Share

    
    
11. KIM M, Gilliland JL, Parnes MF, Bruce C, et al
    BREAST-Q REACT: Qualitative Assessment of the Design, Functionality, and Clinical Utility of a New Score Interpretation Tool.
    Ann Surg Oncol. 2024;31:4498-4511.
    

    >> Share

    
    

    
    BMC Cancer

12. XU C, Sun L, Wang H, Sun J, et al
    Identifying the mechanism of polysaccharopeptide against breast cancer based on network pharmacology and experimental verification.
    BMC Cancer. 2024;24:726.
    

    >> Share

    
    
13. KANG Z, Jin Y, Yu H, Li S, et al
    Relative efficacy of antibody-drug conjugates and other anti-HER2 treatments on survival in HER2-positive advanced breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2024;24:708.
    

    >> Share

    
    
14. LI Y, Han D, Shen C
    Prediction of the axillary lymph-node metastatic burden of breast cancer by (18)F-FDG PET/CT-based radiomics.
    BMC Cancer. 2024;24:704.
    

    >> Share

    
    
15. JORIS S, Giron P, Olsen C, Seneca S, et al
    Identification of RAD17 as a candidate cancer predisposition gene in families with histories of pancreatic and breast cancers.
    BMC Cancer. 2024;24:723.
    

    >> Share

    
    

    
    Breast Cancer

16. TELLI ML, Litton JK, Beck JT, Jones JM, et al
    Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status.
    Breast Cancer. 2024 Jun 13. doi: 10.1007/s12282-024-01603.
    

    >> Share

    
    
17. KITANO S, Tsunashima R, Kato C, Watanabe A, et al
    Validation of late recurrence prediction by gene expression profiles and clinicopathological factors in estrogen receptor-positive breast cancer.
    Breast Cancer. 2024 Jun 11. doi: 10.1007/s12282-024-01602.
    

    >> Share

    
    
18. PURJA S, Nguyen DT, Kim E
    Breast cancer epigenetics: current and evolving treatment.
    Breast Cancer. 2024 Jun 11. doi: 10.1007/s12282-024-01601.
    

    >> Share

    
    

    
    Breast Cancer Res

19. LAINE M, Greene ME, Kurleto JD, Bozek G, et al
    Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancer.
    Breast Cancer Res. 2024;26:95.
    

    >> Share

    
    
20. COLEMAN MF, Cotul EK, Pfeil AJ, Devericks EN, et al
    Hypoxia-mediated repression of pyruvate carboxylase drives immunosuppression.
    Breast Cancer Res. 2024;26:96.
    

    >> Share

    
    
21. LEON-FERRE RA, Whitaker KR, Suman VJ, Hoskin T, et al
    Pre-treatment peripheral blood immunophenotyping and response to neoadjuvant chemotherapy in operable breast cancer.
    Breast Cancer Res. 2024;26:97.
    

    >> Share

    
    
22. BHIMANI J, O'Connell K, Ergas IJ, Foley M, et al
    Trends in chemotherapy use for early-stage breast cancer from 2006 to 2019.
    Breast Cancer Res. 2024;26:101.
    

    >> Share

    
    
23. ZHANG Y, Chen F, Balic M, Creighton CJ, et al
    An essential gene signature of breast cancer metastasis reveals targetable pathways.
    Breast Cancer Res. 2024;26:98.
    

    >> Share

    
    
24. LIEN HC, Lo C, Lee YH, Lin PH, et al
    In situ HER2 RNA expression as a predictor of pathologic complete response of HER2-positive breast cancer patients receiving neoadjuvant chemotherapy and anti-HER2 targeted treatment.
    Breast Cancer Res. 2024;26:100.
    

    >> Share

    
    
25. DU J, Liu X, Sun J, Wu Q, et al
    Trastuzumab-functionalized bionic pyrotinib liposomes for targeted therapy of HER2-positive breast cancer.
    Breast Cancer Res. 2024;26:99.
    

    >> Share

    
    

    
    Breast Cancer Res Treat

26. HOWARD EC, Murray Horwitz ME, Gunn CM, Bak S, et al
    Burden and trajectory of social needs after breast cancer diagnosis at a safety-net hospital.
    Breast Cancer Res Treat. 2024 Jun 8. doi: 10.1007/s10549-024-07389.
    

    >> Share

    
    
27. LI Y, Long W, Zhou H, Tan T, et al
    Revolutionizing breast cancer Ki-67 diagnosis: ultrasound radiomics and fully connected neural networks (FCNN) combination method.
    Breast Cancer Res Treat. 2024 Jun 9. doi: 10.1007/s10549-024-07375.
    

    >> Share

    
    
28. ZHANG BX, Brantley KD, Rosenberg SM, Kirkner GJ, et al
    Second primary non-breast cancers in young breast cancer survivors.
    Breast Cancer Res Treat. 2024 Jun 10. doi: 10.1007/s10549-024-07400.
    

    >> Share

    
    
29. VAN OLMEN JP, Schrijver AM, Stokkel MPM, Loo CE, et al
    Clinical implications of non-breast cancer related findings on FDG-PET/CT scan prior to neoadjuvant chemotherapy in patients with breast cancer.
    Breast Cancer Res Treat. 2024 Jun 12. doi: 10.1007/s10549-024-07331.
    

    >> Share

    
    
30. RAN X, Hu A, Kuang Y, Wang C, et al
    UM171 suppresses breast cancer progression by inducing KLF2.
    Breast Cancer Res Treat. 2024 Jun 14. doi: 10.1007/s10549-024-07372.
    

    >> Share

    
    
31. JACKISCH C, Anastasiadou L, Aulmann S, Argyriadis A, et al
    The REMAR (Rhein-Main-Registry) real-world study: prospective evaluation of the 21-gene breast recurrence score(R) assay in addition to Ki-67 for adjuvant treatment decisions in early-stage breast cancer.
    Breast Cancer Res Treat. 2024 Jun 14. doi: 10.1007/s10549-024-07390.
    

    >> Share

    
    
32. MOKHTARPOUR K, Razi S, Rezaei N
    Ferroptosis as a promising targeted therapy for triple negative breast cancer.
    Breast Cancer Res Treat. 2024 Jun 14. doi: 10.1007/s10549-024-07387.
    

    >> Share

    
    
33. GONCALVES E, Fontes F, Rodrigues JR, Calisto R, et al
    The contribution of second primary cancers to the mortality of patients with a first primary breast cancer.
    Breast Cancer Res Treat. 2024 Jun 13. doi: 10.1007/s10549-024-07361.
    

    >> Share

    
    
34. BHAVE MA, Quintanilha JCF, Tukachinsky H, Li G, et al
    Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice.
    Breast Cancer Res Treat. 2024 Jun 14. doi: 10.1007/s10549-024-07376.
    

    >> Share

    
    
35. BIDISHA B, Sowmya M, Shalini S, Mythri C, et al
    Tamoxifen modulates nutrition deprivation-induced ER stress through AMPK-mediated ER-phagy in breast cancer cells.
    Breast Cancer Res Treat. 2024 Jun 14. doi: 10.1007/s10549-024-07398.
    

    >> Share

    
    

    
    Cancer

36. STERPETTI AV, Gabriele R, Iannone I, Dimarzo L, et al
    National organized screening programs for breast, colorectal, and cervical cancer reduce socioeconomic disparities, but it is not enough.
    Cancer. 2024 Apr 20. doi: 10.1002/cncr.35335.
    

    >> Share

    
    
37. RUAN Y, Heer E, Brenner DR
    Reply to "National organized screening programs for breast, colorectal, and cervical cancer reduce socioeconomic disparities, but it is not enough".
    Cancer. 2024 Apr 20. doi: 10.1002/cncr.35339.
    

    >> Share

    
    

    
    Cancer Cell

38. LI Y, Huang M, Wang M, Wang Y, et al
    Tumor cells impair immunological synapse formation via central nervous system-enriched metabolite.
    Cancer Cell. 2024;42:985-1002.
    

    >> Share

    
    

    
    Cancer Lett

39. WANG S, Xu L, Wang D, Zhao S, et al
    YTHDF1 promotes the osteolytic bone metastasis of breast cancer via inducing EZH2 and CDH11 translation.
    Cancer Lett. 2024 Jun 11:217047. doi: 10.1016/j.canlet.2024.217047.
    

    >> Share

    
    
40. LI SY, Zhang N, Zhang H, Wang N, et al
    Deciphering the TCF19/miR-199a-5p/SP1/LOXL2 pathway: Implications for breast cancer metastasis and epithelial-mesenchymal transition.
    Cancer Lett. 2024;597:216995.
    

    >> Share

    
    
41. ANDRIANI L, Ling YX, Yang SY, Zhao Q, et al
    Sideroflexin-1 promotes progression and sensitivity to lapatinib in triple-negative breast cancer by inhibiting the TOLLIP-mediated autophagic degradation of CIP2A.
    Cancer Lett. 2024 Jun 5:217008. doi: 10.1016/j.canlet.2024.217008.
    

    >> Share

    
    
42. OLUWALANA D, Adeleye KL, Krutilina RI, Chen H, et al
    Biological activity of a stable 6-aryl-2-benzoyl-pyridine colchicine-binding site inhibitor, 60c, in metastatic, triple-negative breast cancer.
    Cancer Lett. 2024 Jun 5:217011. doi: 10.1016/j.canlet.2024.217011.
    

    >> Share

    
    

    
    Clin Breast Cancer

43. HUANG X, Anderson SA, Siegal GP, Wei S, et al
    Comparison of PD-L1 (22C3) Expression in Paired Primary and Metastatic Breast Carcinoma.
    Clin Breast Cancer. 2024;24:e310-e318.
    

    >> Share

    
    
44. CAZZATO V, Stocco C, Scian A, Bonat Guarini L, et al
    Nipple Reconstruction Using the "Arrow Flap" Technique: Outcomes and Patients Satisfaction.
    Clin Breast Cancer. 2024;24:e226-e231.
    

    >> Share

    
    
45. MARIN C, Weiss A, Gooch JC
    Updates in the Surgical Management of Benign and High-Risk Breast Lesions.
    Clin Breast Cancer. 2024;24:278-285.
    

    >> Share

    
    
46. HUANG Z, Tian H, Luo H, Yang K, et al
    Assessment of Oxygen Saturation in Breast Lesions Using Photoacoustic Imaging: Correlation With Benign and Malignant Disease.
    Clin Breast Cancer. 2024;24:e210-e218.
    

    >> Share

    
    
47. WILLEN LPA, Spiekerman van Weezelenburg MA, Bruijsten AA, Broos PPHL, et al
    The Role of Magnetic Resonance Imaging in the Preoperative Staging and Treatment of Invasive Lobular Carcinoma.
    Clin Breast Cancer. 2024;24:e266-e272.
    

    >> Share

    
    
48. MACKENDER E, Dave R, Tudor D, Harvey J, et al
    A Retrospective Audit of the Triage Process Introduced for Breast Referrals Received During the Covid-19 Pandemic.
    Clin Breast Cancer. 2024;24:e219-e225.
    

    >> Share

    
    
49. TASOULIS MK, Lee HB, Kuerer HM
    Omission of Breast Surgery in Exceptional Responders.
    Clin Breast Cancer. 2024;24:310-318.
    

    >> Share

    
    
50. ZIEGENGEIST JL, Elmes JB, Strassels SA, Patel JN, et al
    Alpelisib-Induced Diabetic Ketoacidosis: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System and Review of the Literature.
    Clin Breast Cancer. 2024;24:e204-e209.
    

    >> Share

    
    
51. DOLL A, Kopkash K, Baker J
    Emerging Role of Robotic Surgery in the Breast.
    Clin Breast Cancer. 2024;24:286-291.
    

    >> Share

    
    
52. BUCHHEIT JT, Schacht D, Kulkarni SA
    Update on Management of Ductal Carcinoma in Situ.
    Clin Breast Cancer. 2024;24:292-300.
    

    >> Share

    
    
53. MALLOIZEL-DELAUNAY J, Weyl A, Brusq C, Chaput B, et al
    New Strategy for Breast Cancer Related Lymphedema Treatment by Endermology: ELOCS Phase II Randomized Controlled Trial.
    Clin Breast Cancer. 2024 May 22:S1526-8209(24)00122.
    

    >> Share

    
    
54. ZHANG L, Wang L, Liang R, He X, et al
    An Effective Ultrasound Features-Based Diagnostic Model via Principal Component Analysis Facilitated Differentiating Subtypes of Mucinous Breast Cancer From Fibroadenomas.
    Clin Breast Cancer. 2024 May 17:S1526-8209(24)00120.
    

    >> Share

    
    
55. KUSTIC D
    Size of Extranodal Extension in the Sentinel Lymph Node as a Predictor of Prognosis in Early-Stage Breast Cancer.
    Clin Breast Cancer. 2024 May 13:S1526-8209(24)00118.
    

    >> Share

    
    

    
    Eur J Cancer

56. IGNATIADIS M, Poulakaki F, Spanic T, Brain E, et al
    EBCC-14 manifesto: Addressing disparities in access to innovation for patients with metastatic breast cancer across Europe.
    Eur J Cancer. 2024;207:114156.
    

    >> Share

    
    

    
    Eur J Surg Oncol

57. SCHIPPER RJ, de Bruijn A, van der Sangen MJC, Bloemen JG, et al
    Oncologic outcomes of de-escalating axillary treatment in clinically node-positive breast cancer patients treated with neoadjuvant systemic therapy - A two center cohort study.
    Eur J Surg Oncol. 2024;50:108472.
    

    >> Share

    
    
58. PLOUMEN RAW, Claassens EL, Kooreman LFS, Keymeulen KBMI, et al
    Surgical outcomes and prognosis of HER2+ invasive breast cancer patients with a DCIS component treated with breast-conserving surgery after neoadjuvant systemic therapy.
    Eur J Surg Oncol. 2024;50:108465.
    

    >> Share

    
    
59. HAN W, Shi CT, Wang HN
    Surgery vs. non-surgery for liver metastases from primary breast cancer.
    Eur J Surg Oncol. 2024 May 28:108445. doi: 10.1016/j.ejso.2024.108445.
    

    >> Share

    
    

    
    Eur Radiol

60. KIM HJ, Choi WJ, Gwon HY, Jang SJ, et al
    Improving mammography interpretation for both novice and experienced readers: a comparative study of two commercial artificial intelligence software.
    Eur Radiol. 2024;34:3924-3934.
    

    >> Share

    
    
61. SKAANE P, Osteras BH, Yanakiev S, Lie T, et al
    Discordant and false-negative interpretations at digital breast tomosynthesis in the prospective Oslo Tomosynthesis Screening Trial (OTST) using independent double reading.
    Eur Radiol. 2024;34:3912-3923.
    

    >> Share

    
    
62. KUHL J, Elhakim MT, Stougaard SW, Rasmussen BSB, et al
    Population-wide evaluation of artificial intelligence and radiologist assessment of screening mammograms.
    Eur Radiol. 2024;34:3935-3946.
    

    >> Share

    
    
63. WAUGH J, Evans J, Miocevic M, Lockie D, et al
    Performance of artificial intelligence in 7533 consecutive prevalent screening mammograms from the BreastScreen Australia program.
    Eur Radiol. 2024;34:3947-3957.
    

    >> Share

    
    
64. COZZI A, Di Leo G, Houssami N, Gilbert FJ, et al
    Preoperative breast MRI positively impacts surgical outcomes of needle biopsy-diagnosed pure DCIS: a patient-matched analysis from the MIPA study.
    Eur Radiol. 2024;34:3970-3980.
    

    >> Share

    
    
65. EL KHOURY M, Mesurolle B
    Pre-operative MRI in patients with ductal carcinoma in situ: the ongoing debate.
    Eur Radiol. 2024;34:3967-3969.
    

    >> Share

    
    
66. PEDICONI F, Maroncelli R, Pasculli M, Galati F, et al
    Performance of MRI for standardized lymph nodes assessment in breast cancer: are we ready for Node-RADS?
    Eur Radiol. 2024 Jun 12. doi: 10.1007/s00330-024-10828.
    

    >> Share

    
    

    
    Histopathology

67. LASHEN AG, Toss M, Miligy I, Rewcastle E, et al
    Nottingham prognostic x (NPx): a risk stratification tool in ER-positive HER2-negative breast cancer: a validation study.
    Histopathology. 2024 Jun 13. doi: 10.1111/his.15234.
    

    >> Share

    
    

    
    Int J Cancer

68. ANDREOU M, Jakalski M, Duzowska K, Filipowicz N, et al
    Prelude to malignancy: A gene expression signature in normal mammary gland from breast cancer patients suggests pre-tumorous alterations and is associated with adverse outcomes.
    Int J Cancer. 2024 Jun 8. doi: 10.1002/ijc.35050.
    

    >> Share

    
    

    
    Int J Radiat Oncol Biol Phys

69. HEPEL JT, Leonard KL, Yashar CM, Einck JP, et al
    Phase II Trial of Five-Fraction Accelerated Partial Breast Irradiation Using Noninvasive Image-Guided Breast Brachytherapy.
    Int J Radiat Oncol Biol Phys. 2024;119:878-883.
    

    >> Share

    
    

    
    J Natl Cancer Inst

70. JAGUST P, Powell AM, Ola M, Watson L, et al
    RET overexpression leads to increased brain metastatic competency in luminal breast cancer.
    J Natl Cancer Inst. 2024 Jun 10:djae091. doi: 10.1093.
    

    >> Share

    
    

    
    J Pathol

71. HUTTEN SJ, Messal HA, Lips EH, Sheinman M, et al
    Ductal carcinoma in situ develops within clonal fields of mutant cells in morphologically normal ducts.
    J Pathol. 2024;263:360-371.
    

    >> Share

    
    

    
    J Surg Oncol

72. YOUNG S, Geary A, Zhao X, Kenzik K, et al
    Assessing breast cancer-related lymphedema screening and treatment gaps in a safety-net hospital.
    J Surg Oncol. 2024 Jun 14. doi: 10.1002/jso.27735.
    

    >> Share

    
    

    
    JAMA

73. MANDELBLATT JS, Mainor C, Hudson BI
    The Aspirin Conundrum-Navigating Negative Results, Age, Aging Dynamics, and Equity.
    JAMA. 2024;331:1709-1711.
    

    >> Share

    
    
74. RUBIN R
    Despite New Recommendations, the Debate Over Mammography Guidelines Continues.
    JAMA. 2024;331:1877-1879.
    

    >> Share

    
    

    
    Mod Pathol

75. FARSHID G, Armes J, Dessauvagie B, Gilhotra A, et al
    Development and Validation of a HER2-Low Focused IHC Scoring System with High Inter-Observer Concordance The Australian HER2-low Breast Cancer Concordance Study.
    Mod Pathol. 2024 Jun 7:100535. doi: 10.1016/j.modpat.2024.100535.
    

    >> Share

    
    

    
    NPJ Breast Cancer

76. GRINSHPUN A, Russo D, Ma W, Verma A, et al
    Pure estrogen receptor antagonists potentiate capecitabine activity in ESR1-mutant breast cancer.
    NPJ Breast Cancer. 2024;10:42.
    

    >> Share

    
    
77. CHEN JC, Elsaid MI, Handley D, Anderson L, et al
    Allostatic load as a predictor of postoperative complications in patients with breast cancer.
    NPJ Breast Cancer. 2024;10:44.
    

    >> Share

    
    
78. CHEN D, Xu F, Lu Y, Xia W, et al
    Pyrotinib and trastuzumab plus palbociclib and fulvestrant in HR+/HER2+ breast cancer patients with brain metastasis.
    NPJ Breast Cancer. 2024;10:45.
    

    >> Share

    
    

    
    Oncogene

79. LEE SG, Woo SM, Seo SU, Lee HS, et al
    Non-canonical deubiquitination of OTUB1 induces IFNgamma-mediated cell cycle arrest via regulation of p27 stability.
    Oncogene. 2024;43:1852-1860.
    

    >> Share

    
    
80. SIRKISOON SR, Carpenter RL, Rimkus T, Anderson A, et al
    Correction: Interaction between STAT3 and GLI1/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer.
    Oncogene. 2024 Jun 12. doi: 10.1038/s41388-024-03084.
    

    >> Share

    
    

    
    PLoS One

81. TSENG TH, Chiang SC, Hsu JC, Ko Y, et al
    Cost-effectiveness analysis of granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced febrile neutropenia in patients with breast cancer in Taiwan.
    PLoS One. 2024;19:e0303294.
    

    >> Share

    
    

    
    Proc Natl Acad Sci U S A

82. RUAN ML, Ni WX, Chu JCH, Lam TL, et al
    Iridium(III) carbene complexes as potent girdin inhibitors against metastatic cancers.
    Proc Natl Acad Sci U S A. 2024;121:e2316615121.
    

    >> Share

    
    

    
    Radiol Imaging Cancer

83. ZHANG X, Qiu Y, Jiang W, Yang Z, et al
    Mean Apparent Propagator MRI: Quantitative Assessment of Tumor-Stroma Ratio in Invasive Ductal Breast Carcinoma.
    Radiol Imaging Cancer. 2024;6:e230165.
    

    >> Share

    
    

    
    Radiother Oncol

84. CACHO-DIAZ B, Valdes-Ferrer SI, Chavez-MacGregor M, Salmeron-Moreno K, et al
    Brain metastasis risk prediction model in females with hormone receptor-positive breast cancer.
    Radiother Oncol. 2024 Jun 9:110379. doi: 10.1016/j.radonc.2024.110379.
    

    >> Share

    
    
85. OVERGAARD J, Ccm Hulshof M, Dahl O, Arcangeli G, et al
    ESHO 1-85. Hyperthermia as an adjuvant to radiation therapy in the treatment of locally advanced breast carcinoma. A randomized multicenter study by the European Society for Hyperthermic Oncology.
    Radiother Oncol. 2024;196:110313.
    

    >> Share

    
    

    
    Science

86. WADDELL N, Addala V
    Germline variants alter immune surveillance.
    Science. 2024;384:961-962.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share